Bringing Cancer Treatments From Lab-to-Clinic
ASSIST is driven by the devastating fact that 1 in 5 men and 1 in 6 women will develop cancer. Globally in 2018, 1 in 8 men and 1 in 10 women with cancer will die. If nothing changes, 2040 will see a 71.5% increase in cancer mortalities, dramatically worsening these numbers.
ASSIST is committed to finding safe and effective ways to treat cancer patients all over the world irrespective of their location, ability to pay and stage of cancer. We believe this is possible - think about how the dedicated work of the Global Fund for HIV/AIDS halved the death rate in 20 years!
ASSIST’s team is committed to make cancer a manageable illness for many, rather than treated like a fatal disease. We know it’s through innovation and disruption that transformation takes place. Cancer patients in the developing world face unique treatment access challenges that cannot be met by most of today’s approved cancer drugs. By addressing these heretofore insurmountable challenges, ASSIST expects to change the future of cancer treatment for this largely unserved population. Thereby set an example that can impact communities across the globe.
We believe the bold fuel for this change is NED-170, a combination therapy being developed by NED Biosystems (NED). A public benefit corporation, NED has committed to making NED-170 available to NGOs at cost for developing-world distribution upon regulatory approval.
ASSIST’s mission is simple: to foster Lab-to-Clinic™ therapies and diagnostics that dramatically improve treatment and detection of complex chronic diseases driven by angiogenesis – such as cancer.
(Angiogenesis plays a key role in the diseases comprising the majority of our nation’s most significant public health challenges—namely cancer, coronary artery disease, obesity, Alzheimer’s, Parkinson’s, diabetes, and 60+ additional chronic illnesses.)
ASSIST Medical Research Foundation supports advancing Lab-to-ClinicTM research that will improve treatments and earlier diagnosis of cancer